首页> 外文期刊>Human Pathology >Clinicopathological analysis of intraductal proliferative lesions of prostate: Intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion
【24h】

Clinicopathological analysis of intraductal proliferative lesions of prostate: Intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion

机译:前列腺导管内增生性病变的临床病理分析:前列腺导管内癌,高级前列腺上皮内瘤变和非典型筛状病变

获取原文
获取原文并翻译 | 示例
       

摘要

Intraductal carcinoma of the prostate (IDC-P) and high-grade prostatic intraepithelial neoplasia (HGPIN) are two distinct intraductal lesions; the former is usually associated with invasive carcinoma and has an aggressive course while the latter is considered a precancerous lesion. In addition, there are morphologically lesions not well characterized that fall between IDC-P and HGPIN, consequently termed "atypical cribriform lesions (ACLs)." Using whole mount radical prostatectomy specimens, we evaluated the relationship between these intraductal proliferative lesions and clinicopathological parameters. In this study, ACLs were characterized as a loose cribriform intraductal proliferation with greater architectural complexity when compared to HGPIN, but lacking significant nuclear pleomorphism and/or comedonecrosis. Of 901 radical prostatectomies (2006-2012), IDC-P, ACL, and HGPIN were recorded in 155, 22, 436 cases, respectively. Patients with IDC-P showed more aggressive pathologic features when compared to HGPIN. Invasive cancers in patients with ACL had higher Gleason score (P =.00016), larger tumor volume (P =.025), and more advanced pT stage (P =.023) than those with HGPIN. Cases with ACL showed a higher risk of biochemical recurrence than those with HGPIN and a lower risk than those with IDC-P based on log-rank tests (P =.0045 and P =.0069, respectively). In multivariate analysis, the presence of HGPIN was identified as an independent predictor for infrequent biochemical recurrence (P =.0058). We confirmed IDC-P as a marker of adverse pathologic features and clinical aggressiveness. Our results suggest that ACL should be distinguished from HGPIN and these lesions mandate active clinical surveillance.
机译:前列腺导管内癌(IDC-P)和高级前列腺上皮内瘤变(HGPIN)是两个不同的导管内病变;前者通常与浸润性癌相关,并具有侵袭性病程,而后者则被认为是癌前病变。另外,有些形态学上的病变不能很好地表征为介于IDC-P和HGPIN之间,因此被称为“非典型筛状病变(ACL)”。使用整个安装的前列腺癌根治术标本,我们评估了这些导管内增生性病变与临床病理参数之间的关系。在这项研究中,ACL的特征是与HGPIN相比,具有较松散的筛状导管内增生,具有更高的结构复杂性,但缺乏明显的核多态性和/或粉刺坏死。在901例根治性前列腺切除术(2006-2012年)中,分别记录了155例,22例,436例的IDC-P,ACL和HGPIN。与HGPIN相比,IDC-P患者表现出更具侵略性的病理特征。与HGPIN相比,ACL患者的浸润癌具有更高的格里森评分(P = .00016),更大的肿瘤体积(P = .025)和更晚期的pT分期(P = .023)。根据对数秩检验,ACL病例的生化复发风险高于HGPIN病例,而IDC-P病例则较低(分别为P = .0045和P = .0069)。在多变量分析中,HGPIN的存在被确定为罕见的生化复发的独立预测因子(P = .0058)。我们确认IDC-P是不良病理特征和临床侵袭性的标志物。我们的结果表明,ACL应该与HGPIN区别开来,并且这些病变需要积极的临床监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号